Vir Biotechnology Inc. (NASDAQ:VIR) went up by 13.41% from its latest closing price compared to the recent 1-year high of $75.00. The company’s stock price has collected 21.68% of gains in the last five trading sessions. Press Release reported 14 hours ago that Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Is It Worth Investing in Vir Biotechnology Inc. (NASDAQ :VIR) Right Now?
Opinions of the stock are interesting as 6 analysts out of 8 who provided ratings for Vir Biotechnology Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $54.86. VIR currently public float of 109.35M and currently shorts hold a 10.08% ratio of that float. Today, the average trading volume of VIR was 898.54K shares.
VIR’s Market Performance
VIR stocks went up by 21.68% for the week, with a monthly drop of -0.31% and a quarterly performance of -26.12%, while its annual performance rate touched 142.44%. The volatility ratio for the week stands at 11.46% while the volatility levels for the past 30 days are set at 7.71% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is 8.43% for VIR stocks with a simple moving average of -11.21% for the last 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with BofA Securities repeating the rating for VIR by listing it as a “Buy.” The predicted price for VIR in the upcoming period, according to BofA Securities is $55 based on the research report published on October 05th of the previous year 2020.
Goldman, on the other hand, stated in their research note that they expect to see VIR reach a price target of $54, previously predicting the price at $48. The rating they have provided for VIR stocks is “Buy” according to the report published on September 14th, 2020.
JP Morgan gave a rating of “Neutral” to VIR, setting the target price at $29 in the report published on September 11th of the previous year.
VIR Trading at 8.21% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.27% of loss for the given period.
Volatility was left at 7.71%, however, over the last 30 days, the volatility rate increased by 11.46%, as shares sank -0.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.26% lower at present.
During the last 5 trading sessions, VIR rose by +21.68%, which changed the moving average for the period of 200-days by -6.56% in comparison to the 20-day moving average, which settled at $29.55. In addition, Vir Biotechnology Inc. saw 19.68% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VIR starting from Parrish Jay, who sale 6,945 shares at the price of $26.32 back on Jan 04. After this action, Parrish Jay now owns 222,222 shares of Vir Biotechnology Inc., valued at $182,795 using the latest closing price.
Virgin Herbert, the EVP, Research & CSO of Vir Biotechnology Inc., sale 3,805 shares at $31.19 during a trade that took place back on Dec 22, which means that Virgin Herbert is holding 23,700 shares at $118,683 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -2144.35 for the present operating margin
The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -47.10, with -39.40 for asset returns.
Based on Vir Biotechnology Inc. (VIR), the company’s capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.
When we switch over and look at the enterprise to sales, we see a ratio of 119.29, with the company’s debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.